Randomized and blinded Phase 3 trial to compare the safety and treatment effect of the botulinum toxin A product BoNT/A-DP with placebo for improvement of glabellar lines, followed by an extension part of the study providing BoNT/A-DP to all participants to investigate long term safety and efficacy.
- Registry ID
- EUCTR2015-002164-16
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- CROMA-PHARMA GmbH
- Start date
- 2016-04-01
- Completion date
- 2017-11-16
- Last update
- 2026-08-16
Conditions
- Moderate to severe glabellar lines
Summary
To assess the efficacy of BoNT/A-DP in reducing the severity of glabellar frown lines following treatment (compared with placebo) based on investigator and subject assessment.
Locations
View on source registry